Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
Recruiting now · Not applicable
Conditions studied: Opioid Use
In brief
1. Pain management is a crucial part of general anesthesia surgery. Nociception monitoring can help anesthesiologists better titrate the use of intraoperative analgesic drugs, especially the opioid. 2. Although a variety of nociception monitoring devices have been developed to date, there is not a specific monitoring indicator that serves as the "gold standard" to objectively guide analgesic management in general anesthesia. 3. The MGRNOX index, which is derived from electroencephalogram (EEG), is used to reflect the correlation between noxious stimuli and opioid analgesics in a state of general anesthesia by converting and quantifying the EEG signals collected by the instrument. However, no studies have so far verified the effect of the MGRNOX index-guided analgesic management of general anesthesia on the consumption of opioids in patients. 4. This study aims to explore the effect of MGRNOX index-guided general anesthesia on opioid consumption in patients undergoing laparoscopic cholecystectomy and the primary hypothesis of our study is that using the MGRNOX index to guide intraoperative pain management during general anesthesia can significantly reduce the consumption of remifentanil during the surgery.
Key facts
- Study ID
- NCT07004686
- Run by
- Peking University Shenzhen Hospital
- People needed
- 112
- Starts
- 2025-06-28
- Expected to finish
- 2026-05-30
- Last updated by the study team
- 2025-12-18
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years old and < 65 years old；
- American Society of Anesthesiologists (ASA) class I-II；
- Scheduled to undergo elective laparoscopic cholecystectomy undergeneral anesthesia （without epidural anesthesia, local blocks, or infiltration）
You may not qualify if…
- Pregnancy or lactation period；
- BMI ≥35 kg/m² or <18.5 kg/m²；
- Anticipated difficult airway；
- Previous diagnosis of hypertension；
- History of drug or alcohol abuse within the past 6 months；
- Preoperative acute or chronic pain history (routine preoperative use of opioid or non-opioid analgesics), peripheral or central nervous system-related disorders；
- Definitively diagnosed psychiatric disorders or other neuropsychiatric conditions severely affecting cognitive judgment, history of psychotropic medication use；
- Allergy or intolerance to anesthetic agents；
- Baseline mean arterial pressure (MAP) <60 mmHg or >120 mmHg; baseline heart rate (HR) <45 bpm or >90 bpm (Baseline values defined as first measurement taken in the ward after admission)；
- History of severe underlying diseases (untreated or ongoing peripheral/central cardiovascular diseases, severe hepatic disorders with elevated bilirubin/INR or hypoalbuminemia, severe renal diseases with elevated creatinine, severe pulmonary diseases potentially causing acute respiratory failure or persistent dyspnea)；
- Implanted pacemaker, chronic arrhythmia, preoperative use of prescribed anticholinergics, α2-adrenergic agonists, beta-1 adrenergic antagonists, or antiarrhythmic medications.
Where it is running
- Peking University Shenzhen Hospital — Shenzhen, Guangdong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.